Seeking Alpha

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

--Ocular Therapeutix, Inc., an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been randomized in the HELIOS-3 Phase 3 ...
Hosted on MSN

Ocular Therapeutix outlines superiority trial milestones and broad diabetic label strategy as cash runway extends into 2028

CEO Pravin Dugel described 2025 as "a transformative year for Ocular Therapeutix" and highlighted the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R. Dugel announced, "SOL-R has ...
Seeking Alpha

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label ...

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 ...